BioInfra Co., Ltd. (KOSDAQ:199730)

South Korea flag South Korea · Delayed Price · Currency is KRW
2,380.00
-40.00 (-1.65%)
At close: Jun 29, 2026
Market Cap11.58B -58.4%
Revenue (ttm)23.21B -4.3%
Net Income-9.89B
EPS-2,031.96
Shares Out 4.86M
PE Ration/a
Forward PEn/a
Dividend300.00 (11.32%)
Ex-Dividend DateDec 29, 2025
Volume29,146
Open2,410.00
Previous Close2,420.00
Day's Range2,200.00 - 2,410.00
52-Week Range2,200.00 - 6,330.00
Beta0.27
Analystsn/a
Price Targetn/a
Earnings Daten/a

About BioInfra

BioInfra Co., Ltd. operates as a contract research organization for phase 1 clinical trials. The company provides clinical, which undertakes clinical trials for new drug development approval (Phase I-III) and late clinical trials; immunoassay, which performs pharmacokinetic, toxicokinetic, and biomarker analysis of polymer biopharmaceuticals; and testing and inspection, which provides finished drug product quality inspection, comparative dissolution testing, and long-term stability testing. It also specializes in bioequivalence testing of gener... [Read more]

Industry Commercial Physical and Biological Research
Founded 2007
Country South Korea
Stock Exchange KOSDAQ
Ticker Symbol 199730
Full Company Profile

Financial Performance

In 2025, BioInfra's revenue was 23.15 billion, a decrease of -2.87% compared to the previous year's 23.83 billion. Losses were -9.13 billion, 129.7% more than in 2024.

Financial Statements